Back to results
US 2026/0053961 A1Published application
Heterodimer and radioactive medical use thereof
AssigneeHexin (Suzhou) Pharmaceutical Technology Co., Ltd.
InventorsChangyu SHAN, Dexing ZENG, Yinfei CHEN, Liang MAO
Life of this patent
Estimating the term…
Abstract
Provided is a compound comprising a structure as shown in the figure accompanying the abstract, and use thereof in radionuclide labeling or the preparation of a radionuclide labeling reagent. Also provided is a radionuclide preparation comprising the compound comprising the structure as shown in the figure accompanying the abstract.
Claims21
1-10. (canceled)
A compound comprising a structure in Formula (A),
- wherein,
- Z1 is -L1R1 or —H, and Z2 is -L2R2 or —H, in the provisos that Z1 is -L1R1 and/or Z2 is -L2R2;
- L1 is -(PEG)m-, and the m is an integer selected from 4 to 30;
- L2 is -(PEG)n-, and the n is an integer selected from 4 to 30;
- R1 comprises a peptide sequentially connected by arginine, glycine or sarcosine, and aspartic acid;
- R2 comprises a peptide sequentially connected by asparagine, glycine or sarcosine, cysteine, and arginine;
- R3 is a group of Formula (I) or (II);
- R4 is a group of Formula (III), a group of Formula (IV), or a long-chain fatty acid;
- Q1, Q2, Q3, Q4, and Q5 are each independently selected from a group consisting of —H, —F, —Cl, —Br, —I, C1-C6 linear or branched alkyl, C1-C6 linear or branched fluoroalkyl, and C1-C6 linear or branched fluoroalkoxy;
- x is an integer selected from a group consisting of 1, 2, 3, 4, 5, 6, 7, and 8;
- and
- y is an integer selected from a group consisting of 1, 2, 3, 4, 5, and 6.
9 more elements
The compound according to claim 1, wherein
- Z1 is -L1R1;
- Z2 is -L2R2;
- m is 4;
- and
- n is 4.
2 more elements
Dependencies are inferred from the claim text.